Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday

Vaxart (NASDAQ:VXRT) is expected to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $15.68 million for the quarter.

Vaxart Stock Performance

NASDAQ:VXRT opened at $0.47 on Thursday. The stock has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $0.74. The stock has a market capitalization of $106.92 million, a price-to-earnings ratio of -1.15 and a beta of 1.69. Vaxart has a 1 year low of $0.45 and a 1 year high of $1.41.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.